Advertisement
Singapore markets close in 1 hour 35 minutes

  • Straits Times Index

    3,287.07
    -6.06 (-0.18%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,301.38
    +100.11 (+0.58%)
     

  • FTSE 100

    8,091.74
    +51.36 (+0.64%)
     

  • Bitcoin USD

    64,289.25
    -2,579.12 (-3.86%)
     

  • CMC Crypto 200

    1,389.99
    +7.41 (+0.54%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,332.60
    -5.80 (-0.25%)
     

  • Crude Oil

    82.94
    +0.13 (+0.16%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.12
    -1.36 (-0.09%)
     

  • Jakarta Composite Index

    7,149.72
    -24.81 (-0.35%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Stada says fourth-quarter adjusted net income slips 4 percent

Reuters
The logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel near Frankfurt March 14, 2012. REUTERS/Alex Domanski

FRANKFURT (Reuters) - German drugmaker Stada (STAGn.DE), at the centre of a takeover battle between two private equity consortia, said fourth-quarter adjusted net income slipped 4 percent, revising lower preliminary unaudited results it posted earlier this month after fully taking into account a smaller acquisition.

Stada, which also makes branded non-prescription treatments and diagnostic kits, said quarterly adjusted net income declined to 37.4 million euros (32.57 million pounds), down from 38.9 million a year earlier.

It had initially reported a figure of 44 million euros.

In its statement on Wednesday, Stada did not comment on the takeover bids. It is due to hold a press conference at 0730 GMT.

The German company confirmed its targets for 2017 and 2019.

(Reporting by Ludwig Burger; Editing by Victoria Bryan)